Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6724363 | 0.93 | HRH3 (0.44) | HRH3DRD2HTR1AHTR2AEPHX2 | |
| SCHEMBL6732264 | 0.89 | MEN1 (0.42) | HRH3DRD2HTR1AHTR2AEPHX2 | |
| SCHEMBL6726011 | 0.88 | EPHX2 (0.46) | HRH3EPHX2SIGMAR1 | |
| SCHEMBL6725068 | 0.87 | LMNA (0.46) | HRH3EPHX2 | |
| SCHEMBL6729489 | 0.86 | HRH3 (0.43) | HRH3DRD2HTR1AHTR2A | |
| SCHEMBL6733614 | 0.86 | HRH3 (0.45) | HRH3EPHX2 | |
| SCHEMBL6729282 | 0.86 | LMNA (0.43) | HRH3DRD2HTR1AHTR2AEPHX2 | |
| SCHEMBL6733435 | 0.85 | HTR2A (0.46) | HRH3DRD2HTR1AHTR2AEPHX2 | |
| SCHEMBL6726619 | 0.85 | HRH3 (0.47) | HRH3DRD2HTR1AHTR2AEPHX2 | |
| SCHEMBL6721710 | 0.85 | KMT2A (0.45) | DRD2HTR1AHTR2ASIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014785-A1 | Substituted 1-(piperidin-4-YL)-3-(aryl)-isothioureas, their preparation and therapeutic use | PIERRE FABRE MEDICAMENT (FR) | 2004-01-22 | — | — | US | disclosed |
| US-6583159-B1 | Myocardial ischemia; cytoprotective properties | PIERRE FABRE MEDICAMENT (FR) | 2003-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014785-A1 | Substituted 1-(piperidin-4-YL)-3-(aryl)-isothioureas, their preparation and therapeutic use | AQP1, SLCO2A1, SLCO2B1 | HRH3 1028/4885DRD2 1334/4885HTR1A 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.